METHOD FOR PREDICTION OF SENSITIVITY TO CHEMOTHERAPY IN PATIENTS SUFFERING FROM LYMPHOPROLIFERATIVE DISEASES Russian patent published in 2016 - IPC G01N33/50 

FIELD: medicine.

SUBSTANCE: invention relates to a method for prediction of sensitivity to chemotherapy in patients suffering from lymphoproliferative diseases. Method comprises, in blood serum, determining quantitative levels of markers of thymidine kinases-1 (TK-1) and β2-microglobulin (β2-MG), and after first chemotherapy course activity TK-1. If activity of TK-1 before treatment < 150.0 Du/l, then as a result of 6-8 chemotherapy courses, complete or partial remission is achieved, if level of β2-MG before treatment < 2,200.0 mcg/l, then as a result of 6-8 chemotherapy courses, complete or partial remission is achieved. If activity of TK-1 after 1 chemotherapy course increases by more than 4 times relative to initial value, then as a result of 6-8 chemotherapy courses, complete or partial remission is achieved.

EFFECT: use of disclosed method allows for part of patients to avoid producing inefficient treatment and its collateral toxic complications, improving prognosis of disease by rationalisation of therapy already at first stage.

1 cl, 3 dwg, 3 tbl, 4 ex